Caveat: I have been hilariously off-base in the past. See, for example, my August 31, 2014 blog post
Potential Catalysts.
Updated (8/9/15): To reflect a longer period of pivotal melanoma Phase 3 site activation, and to include as a catalyst the potential approval of Amgen's intralesional agent for metastatic melanoma talimogene laherparepvec (T-Vec).
Updated (8/9/15): To reflect a year-end start to a Phase 1b trial combining PV-10 and an immune checkpoint inhibitor in patients with advanced melanoma.
 |
| Click to enlarge. |
 |
| Click to enlarge. |
No comments:
Post a Comment